Diabetes

SILVER SPRING, Md. — In an effort to help advance the development of devices that automatically monitor blood glucose and provide proper insulin doses in people with Type 1 diabetes, the Food and Drug Administration has issued draft guidance to help investigators and manufacturers as they develop and seek approval for these products.

NEW YORK — Record-breaking attendance, a high-profile keynote speaker, four engaging panel discussions on some of the hottest issues facing the industry and exclusive consumer videos set the stage for the 13th annual Drug Store News Industry Issues Summit held on Tuesday in New York.

ATLANTA — Many elderly patients put themselves at risk for emergency hospitalization due to adverse drug events, according to a new Centers for Disease Control and Prevention study published in the New England Journal of Medicine.

EAST LANSING, Mich. — A drug commonly used to treat Type 2 diabetes may reduce the risk of diabetes-associated cancers, including breast cancer, according to a new study.

OSAKA, Japan — A U.S. subsidiary of Takeda Pharmaceutical has filed for regulatory approval of a drug designed to treat Type 2 diabetes, the company said.

The Takeda Global Research and Development Center filed with the Food and Drug Administration for approval of an alogliptin-metformin combination tablet. The company expects the FDA to review the application within the next 10 months.

COLUMBIA, Mo. — A new tool developed by researchers at the University of Missouri improved both the efficiency and accuracy of acquiring data needed for high-quality diabetes care, according to a new study.

WAUKESHA, Wis. — Hamacher Resource Group will be participating in The Drug Store News Group's Diabetes Leadership Forum, part of the Industry Issues conference, to be held Nov. 29 at the New York Athletic Club. HRG VP Dave Wendland will moderate the discussion for the eighth year in a row. The panel will include six of the leading health and beauty retailers in the country.

NEW YORK — A test commonly used to identify patients with diabetes or those at risk of developing the condition may not produce accurate results among children, according to a new study conducted by researchers at the University of Michigan.

The study, published online ahead of print in the journal Diabetes Care, tested 254 overweight children using both fasting and nonfasting methods. Researchers found that the recommended test, hemoglobin A1C (HbA1C), missed more cases of prediabetes or diabetes, compared with other tests.